Osteoporosis Drugs, Tooth Extraction and Implants

Why Osteoporosis Belongs in the Dental History

Osteoporosis is a chronic bone disease in which bone density falls and the skeleton becomes more fragile, so fractures happen after falls or strains that healthy bone would absorb. It often gives no warning until the first fracture. Treatment aims to prevent fractures, and the medicines used for it act on every bone in the body, the jaw included.

That is the reason an oral and dental health center writes about osteoporosis. The drugs that protect the hip and spine also change how the jawbone renews and heals itself. A tooth extraction, an implant, gum surgery or a bone graft all depend on the jaw repairing bone after the procedure. When a patient takes a medicine that slows bone turnover, the dental team plans these procedures with that in mind.

Osteoporosis medicines fall into two families that do opposite jobs. Antiresorptive drugs, the bisphosphonates and denosumab, slow the cells that break bone down. Bone-building drugs such as teriparatide, abaloparatide and romosozumab stimulate new bone formation. Most dental questions concern the first family, which is linked to a rare jaw complication called osteonecrosis of the jaw.

For the patient, the practical message is short. Any osteoporosis medicine, whether a tablet taken once a week, a yearly infusion or an injection given twice a year, belongs on the medical history form at the first dental visit. The name of the drug, how it is given and how long it has been taken shape the plan for dental surgery more than the diagnosis of osteoporosis on its own. This also applies to drugs stopped some time ago, since some stay in bone for years.

How Bisphosphonates and Denosumab Act on Bone

Bisphosphonates such as alendronate, risedronate, ibandronate and zoledronic acid bind to the mineral surface of bone and are taken up by the cells that resorb it. They remain in the skeleton long after the last dose, which is why a physician can plan a supervised pause after several years of use. Atypical femoral fractures and jaw osteonecrosis are rare side effects.

Denosumab is a monoclonal antibody given as an injection twice a year. It blocks a signal that bone-resorbing cells need in order to form and work, so resorption falls quickly. Its effect does not accumulate in bone the way a bisphosphonate does and fades once a scheduled dose is missed. This difference shapes how each drug is handled around dental surgery.

The two drugs have been compared in routine care. In a Medicare cohort of women with postmenopausal osteoporosis who had not been treated before, 89,115 started denosumab and 389,536 started alendronate (PubMed 38753892). Compared with alendronate, denosumab was associated with 39% fewer major osteoporotic fractures, 36% fewer hip fractures and 43% fewer non-vertebral fractures (PubMed 38753892). The gap grew with time on treatment, from 9% fewer major osteoporotic fractures at year 1 to 31% at year 5 (PubMed 38753892).

Bone-building drugs are usually reserved for higher fracture risk. In a pooled analysis of the FRAME trial with 7,147 patients and the ARCH trial with 4,077, romosozumab reduced new vertebral fractures in women with mild to moderate reduction in kidney function, and adverse events were similar across kidney function groups (PubMed 35466448). The choice among these medicines belongs to the prescribing physician.

Jaw Osteonecrosis at Osteoporosis Doses

Osteonecrosis of the jaw is an area of exposed jawbone that does not heal, usually after an extraction or other surgery in the mouth. It is the complication patients ask about most, and its frequency depends heavily on the dose of the drug. An international task force that reviewed the literature found the highest incidence in cancer patients treated with high, frequent doses of bisphosphonates or denosumab, at 1% to 15% (PubMed 25414052). In the osteoporosis population the estimated incidence was 0.001% to 0.01%, marginally above the general population at below 0.001% (PubMed 25414052).

Real-world data point the same way. In a national database from Taiwan comparing 18,030 alendronate users with 25,615 patients on non-bisphosphonate osteoporosis drugs, jaw osteonecrosis incidence ranged from 6.9 to 8.2 per 10,000 person-years in every group, and alendronate carried no excess risk (HR 0.87, 95% CI 0.47-1.58) (PubMed 24515577). Denosumab has long-term data as well: in the FREEDOM trial and its open-label extension, with up to 10 years of treatment, seven cases of jaw osteonecrosis were reported in the long-term group and six in the crossover group (PubMed 28546097).

Dose is not the only factor. The same task force listed glucocorticoid use, surgery on the upper or lower jaw, poor oral hygiene, chronic inflammation, diabetes mellitus and ill-fitting dentures among the other risk factors (PubMed 25414052). Several of these, such as an infected tooth, a rubbing denture or untreated gum disease, sit within the dental team's reach. The risk at osteoporosis doses is low without being zero, which is why the preparation happens before surgery and the follow-up continues after it.

Tooth Extraction While Taking Osteoporosis Medication

An osteoporosis drug does not by itself rule out an extraction. What changes is the preparation. The dentist needs the drug name, how it is given, the dose and how long it has been used, together with other medicines such as corticosteroids and a record of any cancer treatment. With that, the dental team and the prescribing physician agree on timing.

The most favourable time for dental surgery is before antiresorptive therapy starts. The international task force recommends eliminating or stabilising oral disease before these drugs begin and keeping good oral hygiene during treatment (PubMed 25414052). A patient who is about to start osteoporosis treatment therefore gains from a dental examination first, so that teeth with a poor outlook are treated or removed while bone turnover is still unaffected.

Stopping the drug without medical advice carries its own risk, and denosumab shows why. In an analysis of the FREEDOM trial and its extension, 1001 participants who discontinued denosumab saw their vertebral fracture rate rise from 1.2 per 100 participant-years on treatment to 7.1 after stopping (PubMed 29105841). Among those who had a vertebral fracture after stopping, 60.7% had more than one (PubMed 29105841). The authors concluded that patients who stop denosumab should move quickly to another antiresorptive treatment (PubMed 29105841). For this reason a dental appointment is no reason to skip an injection on one's own initiative; any change is made by the physician who prescribes the drug. After an extraction the socket is followed until the gum closes, and pain that does not settle or bone that stays visible is reported early.

Dental Implants for Patients on Antiresorptive Therapy

An implant relies on bone growing onto its surface, so patients on osteoporosis medicines often ask whether an implant is still possible for them. The published evidence is reassuring at osteoporosis doses and cautious at cancer doses. A systematic review of implant patients aged 75 and over and of the common medical conditions in that age group reported high implant survival in patients receiving low-dose antiresorptive therapy for osteoporosis (PubMed 30328186). The same review found that patients with bone metastases receiving high-dose antiresorptive therapy carry a high risk of complications after implant surgery (PubMed 30328186). Across the geriatric studies it pooled, implant survival was 97.3% at 1 year and 96.1% at 5 years (PubMed 30328186).

These figures describe groups, and each patient is assessed on their own history. Planning an implant for someone on a bisphosphonate or denosumab follows the same logic as planning an extraction: the drug, its route and duration, other risk factors such as diabetes, smoking or steroid use, and the state of the gums. Three-dimensional imaging shows the volume and shape of the bone at the site, and a bone graft, where one would be needed, is weighed against the full medical picture.

The distinction that carries most weight is between the doses used for osteoporosis and the much higher doses used when cancer has spread to bone. Patients who have received cancer-dose antiresorptive therapy are planned more conservatively, and options that avoid surgery in the jawbone are discussed alongside implants. For patients treated for osteoporosis alone, the review gives no reason to treat the diagnosis as a barrier.

What to Tell the Dental Team Before Treatment

A few facts let the dental team plan safely. The first is the name of each bone medicine, current or past, and how it is taken: a weekly or monthly tablet, a yearly infusion, an injection every six months or a daily bone-building injection. The second is how long each has been used and when the last dose was given. The third is whether any of these drugs was ever prescribed for cancer that had spread to bone, since that changes the risk category entirely.

Other medicines and conditions complete the picture. Long-term corticosteroids, diabetes, smoking, a history of gum disease and a denture that rubs or rocks are all worth mentioning, because they appear among the risk factors for jaw complications.

During treatment, daily brushing, cleaning between the teeth and regular dental checks keep the mouth in a state where surgery is less likely to be needed. A sore spot under a denture, a loose tooth or a socket that is slow to heal is worth showing to the dentist early. General bone care continues alongside this: adequate calcium and vitamin D, weight-bearing and resistance exercise, and avoiding high-impact or twisting movements, all agreed with the physician.

The prescribing physician, often an endocrinologist, rheumatologist or geriatrician, decides on the medicine; the dental team decides how to carry out the procedure. Shared information lets most patients on osteoporosis treatment receive the dental care they need.